Introduction: The management of Acute Myeloid Leukemia (AML) (with the exception of acute promyelocytic leukemia) has remained largely unchanged over the past 40Â years. In particular, patients defined as high-risk, according to the 2017 European Leukemia Net recommendations, represent a subgroup with poor response to current therapies that are frequently associated with high-grade toxicity and potentially fatal complications. Areas covered: Preliminary results from an ongoing phase III clinical trial suggest that CPX-351 could represent an interesting treatment option in both induction and âbridge-to-transplantâ settings. In particular, 60- to 75-year-old patients with secondary AML, when treated with CPX-351, exhibit superior overall survival (HRÂ =Â 0.69; PÂ =Â 0.005; median OS 9.56 vs. 5.95Â months), event free survival (HRÂ =Â 0.74; PÂ =Â 0.021), and composite response rate (47.7% vs. 33.3%; PÂ =Â 0.016) as compared to standard â7Â +Â 3â therapy. Herein, we detail the main pharmacological features of CPX-351 and review updated results of clinical trials investigating its employment in AML. Expert commentary: Novel liposome-based drugs display a high therapeutic index and represent a promising alternative to unencapsulated drugs, especially when high-risk features complicate the use of standard treatments. Further efforts in both understanding AML biology and improving nanodrug design are needed.
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti, Claudia;Anelli, Luisa;Zagaria, Antonella;Specchia, Giorgina;Albano, Francesco
2017-01-01
Abstract
Introduction: The management of Acute Myeloid Leukemia (AML) (with the exception of acute promyelocytic leukemia) has remained largely unchanged over the past 40Â years. In particular, patients defined as high-risk, according to the 2017 European Leukemia Net recommendations, represent a subgroup with poor response to current therapies that are frequently associated with high-grade toxicity and potentially fatal complications. Areas covered: Preliminary results from an ongoing phase III clinical trial suggest that CPX-351 could represent an interesting treatment option in both induction and âbridge-to-transplantâ settings. In particular, 60- to 75-year-old patients with secondary AML, when treated with CPX-351, exhibit superior overall survival (HRÂ =Â 0.69; PÂ =Â 0.005; median OS 9.56 vs. 5.95Â months), event free survival (HRÂ =Â 0.74; PÂ =Â 0.021), and composite response rate (47.7% vs. 33.3%; PÂ =Â 0.016) as compared to standard â7Â +Â 3â therapy. Herein, we detail the main pharmacological features of CPX-351 and review updated results of clinical trials investigating its employment in AML. Expert commentary: Novel liposome-based drugs display a high therapeutic index and represent a promising alternative to unencapsulated drugs, especially when high-risk features complicate the use of standard treatments. Further efforts in both understanding AML biology and improving nanodrug design are needed.File | Dimensione | Formato | |
---|---|---|---|
CPX 351 in CPX-351 in acute myeloid leukemia can a new formulation maximize the efficacy of old compounds.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.